Patheon NV Company Profile (NASDAQ:PTHN)

About Patheon NV (NASDAQ:PTHN)

Patheon NV logoPatheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company's segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product's development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTHN
  • CUSIP: N/A
  • Web:
  • Market Cap: $5.07 billion
  • Outstanding Shares: 145,136,000
Average Prices:
  • 50 Day Moving Avg: $34.83
  • 200 Day Moving Avg: $30.49
  • 52 Week Range: $23.72 - $35.01
  • Trailing P/E Ratio: 44.82
  • Foreward P/E Ratio: 23.78
  • P/E Growth: 1.58
Sales & Book Value:
  • Annual Revenue: $1.93 billion
  • Price / Sales: 2.63
  • Book Value: ($1.95) per share
  • Price / Book: -17.93
  • EBIDTA: $352.5 million
  • Net Margins: 5.71%
  • Return on Assets: 4.09%
  • Average Volume: 1.36 million shs.
  • Short Ratio: 2.85
Frequently Asked Questions for Patheon NV (NASDAQ:PTHN)

What is Patheon NV's stock symbol?

Patheon NV trades on the NASDAQ under the ticker symbol "PTHN."

How were Patheon NV's earnings last quarter?

Patheon NV (NASDAQ:PTHN) released its quarterly earnings results on Thursday, June, 8th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01. The firm had revenue of $483.40 million for the quarter, compared to analysts' expectations of $466.08 million. The business's revenue was up 3.2% compared to the same quarter last year. View Patheon NV's Earnings History.

Where is Patheon NV's stock going? Where will Patheon NV's stock price be in 2017?

11 brokerages have issued 12-month target prices for Patheon NV's shares. Their predictions range from $28.00 to $35.00. On average, they anticipate Patheon NV's share price to reach $32.45 in the next twelve months. View Analyst Ratings for Patheon NV.

What are analysts saying about Patheon NV stock?

Here are some recent quotes from research analysts about Patheon NV stock:

  • 1. According to Zacks Investment Research, "Patheon N.V. is a provider of pharmaceutical development and manufacturing services. Patheon N.V. is based in Amsterdam, Netherlands. " (6/15/2017)
  • 2. Jefferies Group LLC analysts commented, "PTHN's results are a further indication of inherent volatility in the CMO business despite long-cycle contracts. FY17 guidance was reduced on FX headwinds and project delays partially offset by the Roche facility acquisition. LT indicators were more positive and we still believe PTHN can generate above industry growth." (3/17/2017)

Who are some of Patheon NV's key competitors?

Who are Patheon NV's key executives?

Patheon NV's management team includes the folowing people:

  • Paul S. Levy, Chairman of the Board
  • James C. Mullen, Chief Executive Officer, Director
  • Stuart R. Grant, Chief Financial Officer, Executive Vice President
  • Gilles A. Cottier, President - Global Pharmaceutical Development Services
  • Franco Negron, President - Drug Product Services
  • Lukas Utiger, President - Drug Substance
  • Michael J. Lehmann, Executive Vice President - Global Sales and Marketing
  • Michael E. Lytton J.D., Executive Vice President - Corporate Development and Strategy
  • Rebecca Holland New, Chief Human Resources Officer and Executive Vice President - Communications and Project Management Office
  • Harry R. Gill III, Senior Vice President - Quality and Continuous Improvement

When did Patheon NV IPO?

(PTHN) raised $625 million in an IPO on Thursday, July 21st 2016. The company issued 30,500,000 shares at a price of $19.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies, UBS Investment Bank, Credit Suisse, Evercore ISI and Wells Fargo Securities acted as the underwriters for the IPO and Baird, Piper Jaffray, Raymond James, William Blair, KeyBanc Capital Markets and Leerink Partners were co-managers.

Who owns Patheon NV stock?

Patheon NV's stock is owned by many different of retail and institutional investors. Top institutional shareholders include JLL ASSOCIATES G.P. V (PATHEON), LTD. (43.10%), Chicago Capital Management LLC (0.41%), Longfellow Investment Management Co. LLC (0.05%) and Havens Advisors LLC (0.04%). Company insiders that own Patheon NV stock include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Institutional Ownership Trends for Patheon NV.

Who bought Patheon NV stock? Who is buying Patheon NV stock?

Patheon NV's stock was acquired by a variety of institutional investors in the last quarter, including Chicago Capital Management LLC, Longfellow Investment Management Co. LLC and Havens Advisors LLC. Company insiders that have bought Patheon NV stock in the last two years include Jll Patheon Co-Investment Fund, Pamela Daley, Paul S Levy and Philip Eykerman. View Insider Buying and Selling for Patheon NV.

How do I buy Patheon NV stock?

Shares of Patheon NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Patheon NV's stock price today?

One share of Patheon NV stock can currently be purchased for approximately $34.96.

MarketBeat Community Rating for Patheon NV (NASDAQ PTHN)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about Patheon NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Patheon NV (NASDAQ:PTHN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.36)
Consensus Price Target: $32.45 (7.18% downside)

Analysts' Ratings History for Patheon NV (NASDAQ:PTHN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Jefferies Group LLCReiterated RatingHold$35.00LowView Rating Details
6/9/2017Leerink SwannDowngradeOutperform -> Market Perform$31.00 -> $35.00LowView Rating Details
6/9/2017Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformLowView Rating Details
6/8/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralLowView Rating Details
5/15/2017Evercore ISIDowngradeOutperform$35.00LowView Rating Details
5/15/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/15/2017Piper Jaffray CompaniesDowngradeOverweight -> NeutralLowView Rating Details
3/17/2017Robert W. BairdDowngradeOutperform -> Neutral$34.00 -> $28.00LowView Rating Details
8/16/2016Credit Suisse GroupInitiated CoverageNeutral$30.00N/AView Rating Details
8/15/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
8/15/2016Morgan StanleyInitiated CoverageOverweight$31.00N/AView Rating Details
8/15/2016KeyCorpInitiated CoverageOverweight$33.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for Patheon NV (NASDAQ:PTHN)
Earnings by Quarter for Patheon NV (NASDAQ:PTHN)
Earnings History by Quarter for Patheon NV (NASDAQ PTHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/8/20174/30/2017$0.19$0.20$466.08 million$483.40 millionViewN/AView Earnings Details
3/16/20171/31/2017$0.22$0.14$463.39 million$457.40 millionViewN/AView Earnings Details
12/20/2016Q416$0.39$0.30$496.27 million$510.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Patheon NV (NASDAQ:PTHN)
2017 EPS Consensus Estimate: $1.36
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.19$0.22$0.21
Q2 20172$0.29$0.37$0.33
Q3 20171$0.38$0.38$0.38
Q4 20172$0.42$0.46$0.44
(Data provided by Zacks Investment Research)


Dividend History for Patheon NV (NASDAQ:PTHN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Institutional Ownership by Quarter for Patheon NV (NASDAQ:PTHN)
Insider Trades by Quarter for Patheon NV (NASDAQ:PTHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2016Paul S LevyDirectorBuy10,000$29.55$295,500.00View SEC Filing  
9/28/2016Paul S LevyDirectorBuy15,000$29.64$444,600.00View SEC Filing  
9/12/2016Paul S LevyDirectorBuy37,000$28.01$1,036,370.00View SEC Filing  
7/26/2016Jll Patheon Co-Investment FundMajor ShareholderBuy815,730$19.85$16,192,240.50View SEC Filing  
7/26/2016Pamela DaleyDirectorBuy48,800$19.85$968,680.00View SEC Filing  
7/21/2016Philip EykermanDirectorBuy28,000$25.00$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Patheon NV (NASDAQ:PTHN)
Latest Headlines for Patheon NV (NASDAQ:PTHN)
DateHeadline logoPatheon NV's (PTHN) "Hold" Rating Reaffirmed at Jefferies Group LLC - July 21 at 8:58 AM logoPatheon NV (PTHN) Given Consensus Rating of "Hold" by Brokerages - July 11 at 8:50 PM logoPatheon NV (NASDAQ:PTHN) Expected to Post Quarterly Sales of $520.43 Million - July 8 at 8:39 AM logoPatheon NV (NASDAQ:PTHN) Expected to Announce Earnings of $0.32 Per Share - July 6 at 4:24 PM logoPatheon to Invest $45 Million, Expanding Capabilities to Support Continued Growth - June 30 at 4:38 AM logoEarnings Review and Free Research Report: Patheon's Q2 Results Topped Estimates; To be Acquired by Thermo Fisher - June 28 at 8:58 AM logoSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Patheon N.V. - PTHN - June 23 at 8:04 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Patheon N.V. to Thermo Fisher Scientific Inc. is Fair to Shareholders - June 22 at 8:58 AM logoPatheon NV (PTHN) Lowered to "Hold" at Zacks Investment Research - June 17 at 10:58 PM logoPatheon NV (PTHN) Receives Consensus Recommendation of "Hold" from Analysts - June 16 at 6:32 PM logoShareholder Alert: Monteverde & Associates PC Announces An Investigation Of Patheon N.V. - PTHN - June 14 at 11:54 PM logoZacks: Brokerages Expect Patheon NV (PTHN) Will Announce Quarterly Sales of $520.43 Million - June 14 at 11:10 AM logo$0.33 Earnings Per Share Expected for Patheon NV (PTHN) This Quarter - June 12 at 4:46 PM logoPatheon NV (PTHN) Downgraded by Raymond James Financial, Inc. to Mkt Perform - June 11 at 9:38 AM logoPatheon NV (PTHN) Stock Rating Lowered by Zacks Investment Research - June 10 at 1:08 PM logoPatheon NV (PTHN) Raised to "Buy" at Zacks Investment Research - June 10 at 7:46 AM logoEarnings up at Patheon ahead of acquisition by Thermo Fisher - June 9 at 3:47 PM logoPatheon NV (PTHN) Cut to Market Perform at Leerink Swann - June 9 at 8:27 AM logoPatheon NV (PTHN) Lowered to Neutral at JPMorgan Chase & Co. - June 8 at 9:02 AM logoPatheon Reports Fiscal 2017 Second Quarter - June 8 at 8:59 AM logoPatheon Holdings tops Street 2Q forecasts - June 8 at 8:59 AM logoPatheon NV (PTHN) Issues Earnings Results - June 8 at 8:50 AM logoPatheon NV (PTHN) Given Market Perform Rating at Raymond James Financial, Inc. - June 8 at 8:32 AM logoThermo Fisher’s Next Big Deal in the Medical Device Industry - June 1 at 8:33 PM logoPatheon NV (PTHN) Receives Consensus Recommendation of "Buy" from Brokerages - May 22 at 6:20 PM logoPatheon NV (PTHN) Expected to Announce Quarterly Sales of $465.97 Million - May 21 at 6:36 PM logoRoyal DSM N.V. -- Moody's changes Royal DSM's outlook to stable from negative; affirms A3/P-2 ratings - May 19 at 12:13 PM logoPatheon NV (PTHN) Upgraded to "Buy" at Zacks Investment Research - May 19 at 7:32 AM logoPatheon Holdings I B.V. -- Moody's places ratings of Patheon Holdings I B.V. on review for upgrade - May 17 at 7:18 PM logoNBPE Announces Valuation Uplift Following the Announced Acquisition of Patheon - May 17 at 8:22 AM logoPatheon NV (PTHN) Downgraded by Jefferies Group LLC to Hold - May 16 at 10:04 PM logoPatheon NV breached its 50 day moving average in a Bullish Manner : PTHN-US : May 16, 2017 - May 16 at 7:04 PM logoThermo Fisher Scientific (Finance I) B.V. -- Moody's affirms Thermo Fisher Scientific's Baa2 senior unsecured rating following Patheon acquisition announcement - May 16 at 7:03 PM logoPTHN Crosses Above Average Analyst Target - May 16 at 9:44 AM logoPatheon NV (PTHN) Expected to Announce Earnings of $0.16 Per Share - May 16 at 9:20 AM logoS&P 500, Nasdaq Composite hit record-highs - May 15 at 6:36 PM logoThermo Fisher to buy Patheon for $5.2 billion to expand biopharma services - May 15 at 6:36 PM logoPiper Jaffray Companies Lowers Patheon NV (PTHN) to Neutral - May 15 at 5:02 PM logoPatheon NV (PTHN) Stock Rating Lowered by William Blair - May 15 at 5:02 PM logoPatheon NV (PTHN) Downgraded by Evercore ISI - May 15 at 4:28 PM logoThermo Fisher Extends Binge With $5.2 Billion Patheon Deal - May 15 at 9:45 AM logoThermo Fisher to buy Patheon in $5.2 billion deal - May 15 at 9:45 AM logoPatheon Completes Sterile Expansion Project at Greenville, NC Manufacturing Site - May 8 at 11:55 AM logoPatheon NV (PTHN) Expected to Announce Quarterly Sales of $465.92 Million - April 27 at 12:20 PM logoPatheon NV (PTHN) Given Average Rating of "Buy" by Analysts - April 25 at 5:51 PM logoZacks: Analysts Anticipate Patheon NV (PTHN) to Announce $0.16 Earnings Per Share - April 25 at 2:15 PM logoDPx Holdings B.V. -- Moody's assigns B2 to DPx Holding's term loan following repricing - April 14 at 6:57 PM logoPatheon NV (PTHN) Receives Average Recommendation of "Buy" from Analysts - March 31 at 1:11 PM logoPatheon Achieved More Outsourced New Drug Approvals Than Any Other Provider According to 2017 PharmSource CMO Scorecard - March 30 at 7:38 PM logoPatheon NV (PTHN) Downgraded by Zacks Investment Research to "Strong Sell" - March 28 at 8:10 AM



Patheon NV (PTHN) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff